Although hyaluronans (HA) has been proved to be effective in the treatment of patients with osteoarthritis and rheumatoid arthritis, the correlations between these effects and the molecular weight (MW) of HA have not been systematically followed. In conclusion, we suggested that the effects of LMW HA were more structure-protective and those of HMW HA were more anti-inflammatory.
Introduction
Hyaluronic Acid (HA), or Hyaluronan, a linear glycosaminoglycan consisting of alternating disaccharide unit structure of D-glucuronic acid and N-acetyl-glucosamine, is a main component of synovial joint fluids and the extracellular matrix of articular cartilage.
1,2 ( Figure 1 ) On the level of molecular biology, HA is manufactured by a group of integral membrane proteins called hyaluronan synthases (HAS). Three human HA synthase (HAS 1, HAS 2 and HAS3) genes have been cloned. 3 HA with higher molecular weight (2 x 10 6 Da) is synthesized by HAS 1 and HAS 2, whereas HA with lower molecular weight (2-3 x 10 5 Da) is synthesized by HAS 3. 4 Regarding the degradation of HA, a class of enzymes named hyaluronidases (HYAL) are involved. Up to now, six associated genes, including HYAL1, HYAL2, HYAL 3, HYAL 4, PH-20/SPAM1, and HYALP1 are cloned in human. 5 Nonsurgical treatments for osteoarthritis (OA) may be characterized as symptom-modifying or disease-modifying drugs. As defined by the Osteoarthritis
Research Society (OARS), disease-modifying drugs are those that are intended to prevent, retard, stabilize, or reverse development of the morphological changes of OA. 6 Hyaluronan has been proven to be a safe and effective symptom-modifying treatment for OA of the knee, in terms of significantly reducing pain and improving function. [7] [8] [9] [10] The original concept for viscosupplementation with HA was based on the hypothesis that HA could help fluid replacement and restore the visco-elasticity of the synovial fluid. 11 However, the fact that all injected HAs are gone within days 12 and yet the clinical benefit lasts for months suggests that there may be the other mechanism through which HAs mediate their clinical benefit. It is now believed that biologic activation of multiple protective mechanisms may explain the long-term clinical benefits [13] [14] [15] . Substantial evidence further recommended that HA in certain patient populations can also have disease-modifying activity. 16 To date, there is no systematic review especially addresses on the role of HA's MW in its effects of symptomatic and structural modifications Some previous studies reported that, in arthritic joint, the average molecular weight and concentration of HA in the synovial fluid is reduced. 17, 18 Other scholars 19 
Materials and Methods

Literatures Search
A review of the literature was carried out based on a PubMed search between 1978
and 2009, using the terms hyaluronan, hyaluronic acid, arthritis, and molecular weight.
Definition of High and Low Molecular Weight of HA
Before comparison, it is very important to clarify the definition of "high" and "low" Orthovisc ® (MW up to 2.9 x 10 6 Da) was regarded as HMW; however, it was considered as LMW in the other report by Karatosun.
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Previous investigators 4 have reported that HA with a higher MW (2 x 10 6 Da) is synthesized by HAS1 and HAS2, whereas HA with a lower MW (2-3 x 10 5 Da) is synthesized by HAS3. Another report indicated that the MW in normal human synovial joint fluid could be as high as 6.3-7.6 x 10 6 Da. 18 Because the highest MW of the current commercially available HA is only up to 6.0 x 10 6 Da, we define the "high" MW as MW greater than 2 x 10 6 Da and define the "low" MW as MW less than 2 x 10 6 Da in the current study. Table 2 .
Results
LOW MOLECULAR WEIGHT HYALURONAN (MW
HIGH MOLECULAR WEIGHT HYALURONAN (MW 2000-6000 kDa)
A recent study by Yasuda 27 recommended that HMW HA (2700 kDa) could down-regulate the catabolic action of fibronectin fragments in rheumatoid arthritis (RA) joints as a potent inhibitor of nuclear factor (NF)-κB which plays a key role in cytokine-mediated induction of inflammation. 28 Recently, Campo 29 Table 3 .
Discussion
THE PAIN-RELIEVING MECHANISM OF HA
We consider the pain-relieving effect of HA is through the mechanism of anti-inflammation over synovium, but not directly through the pain related receptors, which is supported by the following rationales and evidences: First, articular cartilage is both avascular and aneural. Consequently, the pain of OA must come from a different source. The pain generation in OA joints could be ascribed to the following causes: Tendonitis over surrounding soft tissue envelope and muscle strain caused by deformity of OA joint will induce pain; Irritation of subchondral nerve endings resulting from cartilage defect or chondromalacia will induce pain; Mechanical irritation rising from loose body or meniscus tear will induce pain. 32 However, all of these factors will not be corrected in a short period by nonsurgical method; therefore, the mechanism of rapid symptom relief after HA injection should be associated with the other factor, i.e. the synovitis. (Figure 3 Recently, Castro 34 conducted an animal study to study the analgesic activity of a polysaccharide in experimental osteoarthritis in rats. They compared the analgesic effects of intra-articular injected galactomannan polysaccharide derived from Guar gum (GG) and high molecular weight HA (Hylan G-F20). They found that GG, either as a gel or solution, significantly inhibited joint pain similar to the inhibition achieved with Hylan G-F20. This analgesia is independent of the colloidal state. They recommend that the analgesic benefit of viscosupplementation, such as HA injection, may be due to an intrinsic carbohydrate-mediated mechanism rather than to the rheologic properties of the material. We completely agree with their recommendation.
Actually, a lot of cell surface receptors and signal transduction molecular are belonging to the glucosaminoglycans (GAGs) family. The HA is also a kind of GAGs.
We considered that the effect of HA is also through the intrinsic carbohydrate-mediated mechanism as well. HA may occupy the sites of cell surface receptors and then block or change the cell behaviors. In other words, after HA occupy most of the receptor engaging sites on cell surface; other molecular cannot interact with the cell due to limited surface receptor left. Therefore, HA may stabilize the cell through this mechanism.
Conclusion
Currently, no pharmacological managements for OA are approved for the indication of modifying the rate of OA progression. However, evaluation of novel agents and agents with established symptom-relieving activity for structure-modifying effects has become a main focus of research in arthritis. By reviewing the literatures, we recommended that the effects of LMW HA were more structure-protective and those of HMW HA were more anti-inflammatory. 
